Trial Profile
A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerability and Maximum Tolerated Dose of Oral AP24534 in Patients with Refractory or Advanced Chronic Myelogenous Leukemia and other Hematologic Malignancies (AP24534-07-101)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Ponatinib (Primary)
- Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Haematological malignancies; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- Sponsors ARIAD Pharmaceuticals
- 01 Jun 2017 Status changed from active, no longer recruiting to completed.
- 06 Dec 2016 Results of pooled analysis (n=76, data cut-off-2 Feb 2015) of a subgroup of chronic phase -chronic myelogenous leukemia patients from the phase 1 (NCT00660920) and pivotal phase 2 PACE (NCT01207440) trials, presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
- 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology